KYNB Stock Catalyst: FibroGen Sells China Subsidiary to AstraZeneca for Approximately $160 Million

Feb 19, 2025 · 6:16pm ET

Transaction includes $85 million enterprise value and $75 million net cash held in China.

Max move

+79.3%

High of day $26.00

Sparker timei

6:16pm ET

KYNB · Feb 19, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

FibroGen announced on February 20, 2025, the sale of its China subsidiary to AstraZeneca for approximately $160 million. The transaction comprises an enterprise value of $85 million and $75 million in net cash held in China. As of December 31, 2024, FibroGen reported $121.1 million in cash, cash equivalents, and accounts receivable.

The sale is expected to impact FibroGen's financial position, with the company's free float standing at 3,583,400 shares and 4,045,400 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time KYNB sparks.

Download Sniper App →

Catch the next KYNB-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →